Related Experiment Video
Updated: May 28, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Evidence and Pricing: Bridging the Comparative Effectiveness Gap in Federal and State Drug Policy
1, Jens Grueger2, Lucille Sun1
1Curta, Inc., Seattle, WA, USA.
Summary
Contemporary comparative effectiveness research (CER) is vital for informing drug pricing negotiations. Addressing evidence gaps and enhancing transparency are key for federal and state drug pricing programs.
Area of Science:
- Health Economics
- Health Policy
- Comparative Effectiveness Research
Background:
- Drug pricing programs rely on comparative clinical evidence to determine intervention benefits.
- Contemporary comparative effectiveness research (CER) offers real-world insights for these decisions.
Purpose of the Study:
- To identify gaps, challenges, and opportunities in using contemporary CER for drug pricing.
- To develop recommendations for policymakers and manufacturers.
Main Methods:
- Convened seven subject-matter experts and two moderators.
- Discussed contemporary CER use in federal and state drug pricing.
- Synthesized and structured key recommendations.
Main Results:
- Gaps include evidence generation, decision-making transparency, and resource constraints.
- Recommendations focus on clear questions (PICOT framework), transparency, and streamlined processes.
- Manufacturers should leverage resources and tailor evidence.
Conclusions:
- Contemporary CER is critical for informing drug pricing negotiations.
- Rigorous and transparent application of health economics principles is needed.
- Improved evidence evaluation is essential for policy decisions.
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).